Phase 2 GAN Clinical Trials
47 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 47 trials
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 2
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
Metastatic Colorectal CancerFirst-line TreatmentOrganoids+3 more
St. Olavs Hospital148 enrolled1 locationNCT06907342
Recruiting
Phase 2
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled114 locationsNCT06368817
Recruiting
Phase 2
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Classic Hodgkin LymphomaAdvanced Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8+1 more
University of Washington125 enrolled6 locationsNCT06745076
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 2
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
PheochromocytomaPheochromocytoma/ParagangliomaPheochromocytoma and Paraganglioma (PPGL)+2 more
Cambridge University Hospitals NHS Foundation Trust12 enrolled1 locationNCT07680205
Recruiting
Phase 2Phase 3
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
Rectal Cancer Stage IIIRectal Cancer PatientsOrgan Preservation+2 more
Sir Mortimer B. Davis - Jewish General Hospital131 enrolled4 locationsNCT03051464
Recruiting
Phase 2
Chinese Adults With Kidney Disease
Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 2
Atacicept in Multiple Glomerular Diseases
IgANNephrotic SyndromeFSGS+2 more
Vera Therapeutics, Inc.250 enrolled1 locationNCT06983028
Recruiting
Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled26 locationsNCT07146906
Recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
GM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros B.V.21 enrolled3 locationsNCT07399704
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled29 locationsNCT06989359
Recruiting
Phase 2
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Advanced Pheochromocytoma and ParagangliomaPCPG
Jazz Pharmaceuticals90 enrolled9 locationsNCT07282587
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.73 enrolled2 locationsNCT07616700
Recruiting
Phase 2
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Minimal Change Disease (MCD)
Everest Medicines (China) Co.,Ltd.45 enrolled2 locationsNCT07614477
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830